Clovis Oncology nets $129mm in initial public offering

Specialty cancer pharmaco Clovis Oncology Inc. has netted $129mm in its initial public offering of 10.7mm shares (including partial exercise of the overallotment) at $13, the low end of its $13-15 price range. The company initially planned to sell only 9.3mm shares. Existing stockholders, directors, and executive management have agreed to buy 4.3mm, or 43%, of the shares at the IPO price.